Ocugen Grants CEO New Performance-Based Equity Award

Ocugen ( (OCGN) ) has issued an update.

In the fourth quarter of 2025, Ocugen’s Board, following a review by its Compensation Committee and external consultant, approved an additional grant of 9,369,604 performance restricted stock units to Chief Executive Officer and founder Dr. Shankar Musunuri, beyond his regular annual equity award, to be granted on January 2, 2026. The three-year award, covering a performance period through December 31, 2028, is structured so that two-thirds of the units vest upon achieving specified regulatory milestones and one-third upon reaching a stock performance milestone, with any unachieved units by the end of the period or upon Dr. Musunuri’s termination of service forfeited, underscoring Ocugen’s use of performance-based equity to align executive incentives with operational and market outcomes.

The most recent analyst rating on (OCGN) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Ocugen stock, see the OCGN Stock Forecast page.

Spark’s Take on OCGN Stock

According to Spark, TipRanks’ AI Analyst, OCGN is a Neutral.

Ocugen’s overall stock score is primarily impacted by its weak financial performance, characterized by ongoing losses and high leverage. Technical indicators also suggest a bearish trend. While the earnings call and corporate events provide some positive developments, they are insufficient to offset the broader financial and technical challenges.

To see Spark’s full report on OCGN stock, click here.

More about Ocugen

Ocugen, Inc. is a biopharmaceutical company focused on developing therapies and vaccines, with its leadership and incentive structures closely linked to regulatory and stock performance milestones in the healthcare sector.

Average Trading Volume: 4,824,388

Technical Sentiment Signal: Buy

Current Market Cap: $462.2M

For a thorough assessment of OCGN stock, go to TipRanks’ Stock Analysis page.